CompletedNCT02573168
GeneSight Testing to Guide Antipsychotic Treatment
About this title
Read the official source — NCT02573168Interventional studyAges 18+CanadaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- TorontoSee all locations and recruitment
Study information
Study start dateStarted: January 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 103
- Sponsor
- St. Joseph's Healthcare Hamilton
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Genetic, Other
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02573168
- Official title
Show the full official title
A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Change in Weight Following Antipsychotic Treatment in Patients Suffering From Disorders Indicated for Antipsychotic Utilization
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is St. Joseph's Healthcare Hamilton.
Who was this study for?
Listed age limits: from 18 years.
